Amyloid neuropathies

Mount Sinai Journal of Medicine

Volumn 79, Issue 6, 2012, Pages 733-748

  Shin, Susan C ^a   Robinson Papp, Jessica ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

amyloid; autonomic; genetic; neuropathy

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; APOLIPOPROTEIN A1; CAPSAICIN; DIFLUNISAL; DULOXETINE; GABAPENTIN; GELSOLIN; NORTRIPTYLINE; PREALBUMIN; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TAFAMIDIS; TRICYCLIC ANTIDEPRESSANT AGENT;

AMINO ACID SUBSTITUTION; AMYLOID NEUROPATHY; ARTICLE; AUTONOMIC NEUROPATHY; CARPAL TUNNEL SYNDROME; CHROMOSOME 18; COGNITIVE DEFECT; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROMYOGRAPHY; ELECTROPHYSIOLOGY; FAMILIAL AMYLOID POLYNEUROPATHY; HUMAN; LIVER TRANSPLANTATION; MALAISE; MUSCLE ATROPHY; MUSCLE WEAKNESS; MUTATION RATE; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; POINT MUTATION; PREVALENCE; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REFLEX DISORDER; SEDATION; SENSORIMOTOR NEUROPATHY; SENSORY DYSFUNCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; URINE RETENTION; VIBRATION SENSE; WEIGHT REDUCTION;

AGE FACTORS; AMYLOID NEUROPATHIES; AMYLOID NEUROPATHIES, FAMILIAL; COMBINED MODALITY THERAPY; HUMANS; PHYSICAL EXAMINATION; PROGNOSIS; RISK FACTORS;

EID: 84871288789     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.21352     Document Type: Article

References (76)

1. Kyle RA, Kelly JJ, Dyck PJ., Amyloidosis and neuropathy. In:, Dyck PH, Thomas PK, eds. Peripheral Neuropathy. 4th ed. Philadelphia, PA: Elsevier Saunders; 2005: 2427-2451.
2. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010; 17: 101-104.
3. Andrade C., A peculiar form of peripheral neuropathy: familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-427.
4. Araki S, Mawatari S, Ohta M, et al. Polyneuritic amyloidosis in a Japanese family. Arch Neurol 1968; 18: 593-602.
5. Andersson R., Familial amyloidosis with polyneuropathy: a clinical study based on patients living in northern Sweden. Acta Med Scand Suppl 1976; 590: 1-64.
6. Costa PP, Figueira A, Bravo F., Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci U S A 1978; 75: 4499-4503.
7. Planté-Bordeneuve V, Said G., Familial amyloid polyneuropathy. Lancet Neurol 2011; 10: 1086-1097.
8. Wallace MR, Naylor SL, Kluve-Beckerman B, et al. Localization of the human prealbumin gene to chromosome 18. Biochem Biophys Res Commun 1985; 129: 753-758.
9. Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003; 10: 160-184.
10. Uemichi T, Liepnieks JJ, Waits RP, et al. A trinucleotide deletion in the transthyretin gene (V122) in a kindred with familial amyloidotic polyneuropathy. Neurology 1997; 48: 1667-1670.
11. Benson M, Kincaid J., The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36: 411-423.
12. Hund E, Linke RP, Willig F, et al. Transthyretin associated neuropathic amyloidosis: pathogenesis and treatment. Neurology 2001; 56: 431-435.
13. Planté-Bordeneuve V, Carayol J, Ferreira A, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003; 40: e120.
14. Misu K, Hattori N, Nagamatsu M., Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan: clinicopathological and genetic features. Brain 1999; 122 (part 10): 1951-1962.
15. Ikeda S, Nakazato M, Ando Y, et al. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002; 58: 1001-1007.
16. Sousa A, Andersson R, Drugge U, et al. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 1993; 43: 288-294.
17. Sousa A, Coelho T, Lobato L, et al. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995; 60: 512-521.
18. Araki S, Ando Y., Transthyretin-related familial amyloidotic polyneuropathy-progress in Kumamoto, Japan (1967-2010). Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 694-697.
19. Ikeda S, Takei Y, Tokuda T, et al. Clinical and pathological findings of non-Val30Met TTR type familial amyloid polyneuropathy in Japan. Amyloid 2003; 10 (suppl 1): 39-47.
20. Soares ML, Coelho T, Sousa A, et al. Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden. Eur J Hum Genet 2004; 12: 225-237.
21. Koike H, Morozumi S, Kawagashira Y, et al. The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid 2009; 16: 142-148.
22. Planté-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007; 69: 693-698.
23. Dyck PJ, Lambert EH., Dissociated sensation in amyloidosis: compound action potential, quantitative histologic and teased-fiber, and electron microscopic studies of sural nerve biopsies. Arch Neurol 1969; 20: 490-507.
24. Thomas PK, King RH., Peripheral nerve changes in amyloid neuropathy. Brain 1974; 97: 395-406.
25. Said G, Ropert A, Faux N., Length-dependent degeneration of fibers in Portuguese amyloid polyneuropathy: a clinicopathologic study. Neurology 1984; 34: 1025-1032.
26. Soprano DR, Herbert J, Soprano KJ, et al. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem 1985; 260: 11793-11798.
27. Brett M, Persey MR, Reilly MM, et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain 1999; 122: 183-190.
28. Uemichi T, Uitti RJ, Koeppen AH, et al. Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch Neurol 1999; 56: 1152-1155.
29. Ellie E, Camou F, Vital A, et al. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). Neurology 2001; 57: 135-137.
30. Blevins G, Macaulay R, Harder S, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transtryretin variant Tyr69His. Neurology 2003; 60: 1625-1630.
31. Goren H, Steinberg MC, Farboody GH., Familial oculoleptomeningeal amyloidosis. Brain 1980; 103: 473-495.
32. Uitti RJ, Donat JR, Rozdilsky B, et al. Familial oculoleptomeningeal amyloidosis: report of a new family with unusual features. Arch Neurol 1988; 45: 1118-1122.
33. Monaco HL, Rizzi M, Coda A., Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 1995; 268: 1039-1041.
34. Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A 2004; 101: 2817-2822.
35. Dickson PW, Aldred AR, Marley PD, et al. High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain. Biochem Biophys Res Commun 1985; 127: 890-895.
36. Li X, Masliah E, Reixach N, et al. Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective? J Neurosci 2011; 31: 12483-12490.
37. Murakami T, Ohsawa Y, Zhenghua L, et al. The transthyretin gene is expressed in Schwann cells of peripheral nerves. Brain Res 2010; 1348: 222-225.
38. Simmons Z, Specht C., The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis 2010; 11: 145-157.
39. Kelly JJ Jr., The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve 1983; 6: 504-509.
40. Kim DH, Zeldenrust SR, Low PA, et al. Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy. Muscle Nerve 2009; 40: 363-370.
41. Yang N, Lee M, Chao C, et. al. Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser. Neurology 2010; 75: 532-538.
42. Li K, Kyle RA, Dyck PJ., Immunohistochemical characterization of amyloid proteins in sural nerves and clinical associations in amyloid neuropathy. Am J Pathol 1992; 141: 217-226.
43. Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011; 68: 195-199.
44. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63: 2104-2110.
45. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005; 6: 253-260.
46. Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1998; 280: 1590-1595.
47. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346-356.
48. Simpson DM, Brown S, Tobias J,; NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008; 70: 2305-2313.
49. Estanislao L, Carter K, McArthur J, et al. Lidoderm-HIV Neuropathy Group. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr 2004; 37: 1584-1586.
50. Sekijima Y, Dendle M, Kelly J., Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006; 13: 236-249.
51. Berk J, Dyck P, Obici L, et al. Familial Amyloidosis Consortium. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid 2011; 18 (suppl 1): 191-192.
52. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785-792.
53. Lladó L, Baliellas C, Casasnovas C, et al. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl 2010; 16: 1386-1392.
54. Herlenius G, Wilczek HE, Larsson M, et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004; 77: 64-71.
55. Yamashita T, Ando Y, Okamoto S, et. al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012; 78: 637-643.
56. Yamamoto S, Wilczek HE, Nowak G, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007; 7: 2597-2604.
57. Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006; 33: 609-618.
58. Kurosawa T, Igarashi S, Nishizawa M, et al. Selective silencing of a mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun 2005; 337: 1012-1018.
59. Tanaka K, Yamada T, Ohyagi Y, et al. Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J Neurol Sci 2001; 183: 79-84.
60. Eriksson M, Schönland S, Yumlu S, et al. Hereditary apolipoprotein A1-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn 2009; 11: 257-262.
61. Testro AG, Brennan SO, Macdonell RA, et al. Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: outcome of hepatorenal transplantation. Liver Transpl 2007; 13: 1028-1031.
62. Meretoja J., Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms: a previously unrecognized heritable syndrome. Ann Clin Res 1969; 1: 314-324.
63. Maury CP., Immunohistochemical localization of amyloid in Finnish hereditary amyloidosis with antibodies to gelsolin peptides. Lab Invest 1991; 64: 400-404.
64. Chastan N, Baert-Desurmont S, Saugier-Veber P, et al. Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the Asp187Tyr mutation in the GSN gene. Muscle Nerve 2006; 33: 113-119.
65. Kiuru S, Salonen O, Haltia M., Gelsolin-related spinal and cerebral amyloid angiopathy. Ann Neurol 1999; 45: 305-311.
66. Matsuda M, Gono T, Morita H, et al. Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol 2011; 18: 604-610.
67. Gertz MA, Lacy MQ, Dispenzieri A., Amyloidosis. Hematol Oncol Clin North Am 1999; 13: 1211-1233.
68. Adams D, Lozeron P, Theaudin M, et al. Varied pattern of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients. Amyloid. 2011; (18 suppl 1): 93-95.
69. Luigetti M, Papacci M, Bartoletti S, et al. AL amyloid neuropathy mimicking a chronic inflammatory demyelinating polyneuropathy. Amyloid 2012; 19: 53-55.
70. Tracy J, Dyck P, Dyck J., Primary amyloidosis presenting as upper limb multiple mononeuropathies. Muscle Nerve 2010; 41: 710-715.
71. Perfetto F, Moggi-Pignone A, Livi R, et al. Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol 2010; 6: 417-429.
72. Nordborg C, Kristensson K, Olsson Y, et al. Involvement of the autonomous nervous system in primary and secondary amyloidosis. Acta Neurol Scand 1973; 49: 31-38.
73. Tsunoda I, Awano H, Kayama H., Idiopathic AA amyloidosis manifested by autonomic neuropathy vestibulocholeopathy and lattice corneal dystrophy. J Neurol Neurosurg Psychiatry 1994; 57: 635-637.
74. Valleix S, Gillmore JD, Bridoux F, et al. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med 2012; 366: 2276-2283.
75. Sekijima Y, Uchiyama S, Tojo K, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 2011; 42: 1785-1791.
76. Wang AK, Gorevic PD., Neurologic improvement after cervical decompression in wild-type transthyretin amyloidosis. In:, Dyck PJ, Dyck PJB, Klein CJ, et al, eds. Companion to Peripheral Neuropathy: Illustrated Cases and New Developments. Philadelphia, PA: Elsevier Saunders; 2010: 145-149.